Inotersen
Inotersen is an antisense oligonucleotide medication used to treat hereditary transthyretin amyloidosis (hATTR) with polyneuropathy in adults. It works by reducing the production of transthyretin protein in the liver, thereby slowing the progression of nerve damage caused by the accumulation of abnormal amyloid deposits.
Inotersen is an antisense therapy that treats hereditary transthyretin amyloidosis by reducing TTR protein production to slow nerve damage progression.
Key facts at a glance
- ATC
- N07XX15
- RxNorm
- 2099289
- Generic
- Inotersen
- Class
- atc-n07
- Brands
- Tegsedi
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- prefilled syringe
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Dosage and administration
- Usual dose
- 500mg twice daily
- Maximum
- consult physician
- Frequency
- every 12 hours
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 250mg twice daily
- Maximum
- consult physician
- Frequency
- every 12 hours
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 400mg daily
- Maximum
- consult physician
- Frequency
- once daily
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
Overdose information
Special Populations
10 groupspregnancy
first trimesteravoid if possible
use only if potential benefits outweigh potential risks to the fetus
regular fetal monitoring and ultrasound assessments
Use with caution and monitor for adverse effects.
pregnancy
second trimesteravoid if possible
continue only if benefits outweigh risks, consider discontinuation if pregnancy confirmed
regular fetal monitoring
Use with caution and monitor for adverse effects.
pregnancy
third trimesteravoid if possible
use only if benefits outweigh risks, close monitoring required
fetal monitoring and assessment of maternal condition
Use with caution and monitor for adverse effects.
lactation
breastfeedingnot recommended
discontinue breastfeeding or discontinue drug, considering importance of drug to mother
monitor infant for adverse effects
geriatric
elderly 65 plusno specific dose adjustment required
use with caution due to increased risk of thrombocytopenia and glomerulonephritis in elderly
more frequent monitoring of platelet counts and renal function
Use with caution and monitor for adverse effects.
pediatric_age
children under 18not established
not recommended for use in pediatric patients due to lack of safety and efficacy data
not applicable
renal_impairment
mild renal impairmentno dose adjustment recommended
monitor renal function closely, increased risk of glomerulonephritis
regular monitoring of serum creatinine and urinalysis
Use with caution and monitor for adverse effects.
renal_impairment
moderate severe renal impairmentuse with caution
use only if benefits outweigh risks, close monitoring required
frequent monitoring of renal function and platelet counts
Use with caution and monitor for adverse effects.
hepatic_impairment
mild hepatic impairmentno dose adjustment recommended
use with caution, monitor hepatic function
regular monitoring of liver function tests
Use with caution and monitor for adverse effects.
hepatic_impairment
moderate severe hepatic impairmentnot studied
use not recommended due to lack of data
monitor hepatic function if used
Statistics and clinical data
Drug class
Inotersen is a transthyretin-directed antisense oligonucleotide
Primary indication
Approved for adult patients with hATTR with polyneuropathy
FDA approval year
FDA approved Inotersen in October 2018
Mechanism of action
Binds to TTR mRNA and inhibits TTR protein production
Inotersen is indicated for the treatment of hereditary transthyretin amyloidosis (hATTR amyloidosis) in adults with Stage 1 or Stage 2 polyneuropathy. This is a rare genetic condition where abnormal transthyretin proteins form amyloid deposits that damage nerves and other organs.
Inotersen is an antisense oligonucleotide that binds to messenger RNA (mRNA) encoding transthyretin (TTR), preventing the translation of TTR protein. By reducing hepatic production of TTR, it decreases the amount of abnormal protein available to form amyloid deposits in peripheral nerves and other tissues.
Inotersen is administered as a weekly subcutaneous injection. Regular monitoring for thrombocytopenia and kidney function is required due to risk of serious side effects including glomerulonephritis. Monitoring of platelet counts and renal function should occur before and during treatment. Patients should be educated on signs of bleeding or kidney problems. Anticoagulant medications may increase bleeding risk.
Contraindications
Conditions and patient states where this medication should be avoided or used with caution.
Do not use (1)
Known allergy to this medication or its components
Use caution (1)
Consult healthcare provider for benefits vs risks assessment
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy